{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003978","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.363685+00:00","generated_at":"2026-06-07T02:13:27.431444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Karyopharm reports preliminary FY2023 total revenue ~$146M, XPOVIO net product revenue ~$112M, meeting guidance","bullets":["Full year 2023 total revenue ~$145.9M; U.S. XPOVIO net product revenue ~$112.0M; Q4 total revenue ~$33.6M.","Cash and investments ~$192M as of Dec 31, 2023, enabling cash runway into late 2025.","Key 2023 achievements include NCCN guideline upgrade for XVd, patent extension to Jul 2033, and ~20% workforce reduction.","Near-term catalysts: Phase 3 readouts in 2H 2024 for multiple myeloma, enrollment completion in EC-042 for endometrial cancer, and updated myelofibrosis data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003978","json":"https://secwatch.observer/filing/0001193125-24-003978.json","markdown":"https://secwatch.observer/filing/0001193125-24-003978.md","text":"https://secwatch.observer/filing/0001193125-24-003978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/0001193125-24-003978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/d86824d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:13:27.431444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f237d0f03071d42ce529760917229c28979ec83","claim":"Karyopharm Therapeutics Inc. reported fourth quarter and full year 2023 results: revenue approximately $146 million.","evidence_excerpt":"Endometrial Cancer and Myelofibrosis – – Preliminary Unaudited Full Year 2023 Total Revenue and U.S. XPOVIO ® (selinexor) Net Product Revenue Expected to be Approximately $146 Million and $112 Million, Respectively, Meeting Company’s Guidance – – Potential for Selinexor to be a Novel Maintenance Treatment for Patients with TP53 Wild-Type Endometrial Cancer","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524003978/0001193125-24-003978-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Revenue","value":"approximately $146 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}